Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results
February 10, 2016 8:57 AM EST
Slowing sales of Seattle Genetics' (NASDAQ: SGEN) ADCETRIS led Piper Jaffray analyst, Edward Tenthoff, to reduce his overall value for the therapy to $1.5 billion from $1.6 billion. This leads to a lower target price for shares of Seattle Genetics of $33 (from $44). The firm maintained a Neutral rating.
ADCETRIS sales grew 27% annually to $226 million in 2015, but we forecast growth will slow to 17% to $265 million (guidance is $255-$275 million) in 2016. ADCETRIS is currently in three Phase III trials that... More
February 10, 2016 7:26 AM EST
Cantor Fitzgerald upgraded Seattle Genetics (NASDAQ: SGEN) from Hold to Buy with a price target of $38.00.
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $29.04 yesterday.
...
More
February 9, 2016 4:05 PM EST
Seattle Genetics (NASDAQ: SGEN) reported Q4 EPS of ($0.18), $0.02 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $93.5 million versus the consensus estimate of $88.28 million.
In 2015, we demonstrated significant progress across our corporate priorities. For ADCETRIS, we achieved... More
